Embecta Corp. (EMBC)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$5.80+1.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · EMBC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -76.2% |
| Our one-year growth estimate | diamond | 5.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 82.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers · Company calendar date is not available
EMBC — earnings miss
Dated 2026-05-05
Results of Operations and Financial Condition. On May 5, 2026, Embecta Corp. issued a press release (the “Press Release”) regarding its results for the quarter ended March 31, 2026. The Press Release is furnished as Exhibit 99.1 to this report.
Why it matters: Paying off debt shows financial health and helps future investments.
Supportive ifManagement reports repayment of more than $53 million in debt.
Worry ifManagement does not report any progress on paying off debt.
Why it matters: The dividend cut may affect investor sentiment and stock price. This reflects how the market views embecta's financial health.
Worry ifThe share price stays the same or goes up after the dividend cut announcement.
Less concerning ifThe share price drops a lot after the dividend cut announcement.
Why it matters: Paying off more debt shows better financial health. This helps long-term growth plans.
Supportive ifManagement reports that debt repayment will be over $150 million in 2026.
Worry ifDebt repayment falls below $150 million in 2026.
Why it matters: The review may lead to cost savings or changes. This affects profits and efficiency.
Watch forManagement shares plans to save costs. These changes can help profit margins.
Also watch forManagement says there are no major changes or savings from the review.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$211 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $542 loss on $10,000 · 5.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,053 loss on $10,000 · 80.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The launch of this product could drive new revenue streams and strengthen market position in diabetes care.
Supportive ifManagement confirms the GLP-1 small pack format launch in the U.S. is on track for fiscal fourth quarter.
Worry ifThe launch is delayed or canceled.
Why it matters: These payments depend on the sales of the Aidaptus auto-injector. Strong sales would confirm the acquisition's value.
Supportive ifOwen Mumford's net sales are over £50 million in the three years after the buy.
Worry ifOwen Mumford's product sales are lower than expected. This means no performance payments.
Why it matters: If adjusted earnings per share drop below this level, it may show profit issues. This could change how investors feel.
Worry ifAdjusted earnings per share reported below $0.50 in the next quarter.
Less concerning ifAdjusted earnings per share reported above $0.50 in the next quarter.
Why it matters: Successful product launches can boost sales and market position. Delays may show problems.
Supportive ifAnnouncement of successful launches of pen needles or syringes in the U.S.
Worry ifNo new product launches announced in the U.S. market within the next quarter.
Why it matters: A larger decline would signal ongoing issues in the U.S. market and hurt investor confidence.
Worry ifQ3 U.S. revenue decline worse than -24.6% year over year.
Less concerning ifU.S. revenue decline less than -24.6% year over year.
Why it matters: Paying off debt is key for financial health. Missing targets could raise financial stability concerns.
Supportive ifManagement reports repayment of at least $50 million in debt in the next quarter.
Worry ifManagement does not report any major debt repayment in the next quarter.
Why it matters: Keeping the dividend shows a commitment to shareholders. This is important during tough times.
Supportive ifEmbecta declares a dividend of $0.15 per share in Q3 2026.
Worry ifEmbecta cuts the dividend below $0.15 per share in Q3 2026.
Why it matters: These payments depend on net sales of the Aidaptus auto-injector platform. They signal how well the acquisition is performing.
Supportive ifOwen Mumford's net sales from the Aidaptus platform are over £50 million in three years.
Worry ifNet sales of the Aidaptus platform fail to reach £50 million in the first three years.
Why it matters: Better operating income shows that costs are managed well. It also means more efficiency.
Supportive ifOperating income increases to above $40M in Q3 2026.
Worry ifOperating income remains below $35M in Q3 2026.
Why it matters: Updates on the share buyback program may show how much management trusts the company.
Supportive ifManagement says they have finished a big part of the $100 million buyback program.
Worry ifNo updates or signs of share buybacks happening within the planned time.